Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 229

Sort by

Sort Order Select

Journal Articles

Elevation of fetal hemoglobin is a biomarker for response to decitabine in AML: Results of the AML21 randomized phase III trial of the EORTC leukemia group, gimema and german MDS study group

Blood (2025) 146 (Supplement 1): 1709.

https://doi.org/10.1182/blood-2025-1709

Published: 2025

Journal Articles

Asciminib for relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) and lymphoid blast crisis of chronic myeloid leukemia (LBC-CML) in Italy: A Campus ALL real life study

Matteo Dragani, Patrizia Chiusolo, Giulia Rivoli, Marco Cerrano, Lara Aprile, Erika Borlenghi, Benedetta Cambò, Eleonora De Bellis, Marzia Defina, Ludovica Fucci, Rachele Giubbolini, Carmela Gurrieri, Cristina Papayannidis, Elisa Roncoroni, Marina Aurora Urbano, Robin Foà, Sabina Chiaretti

Blood (2025) 146 (Supplement 1): 1572.

https://doi.org/10.1182/blood-2025-1572

Published: 2025

Journal Articles

Clinical impact of untargeted baseline plasma metabolomics in newly diagnosed diffuse large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 3560.

https://doi.org/10.1182/blood-2025-3560

Published: 2025

Journal Articles

First results of the Phase III GIMEMA ALL2820 trial comparing ponatinib plus blinatumomab to imatinib and chemotherapy for newly diagnosed adult ph+ acute lymphoblastic leukemia patients

Sabina Chiaretti, Mariangela Di Trani, Cristina Skert, Loredana Elia, Giada Almici, Irene Della Starza, Deborah Cardinali, Vittorio Bellomarino, Stefano Soddu, Monica Messina, Martina Rachele Marino, Maria Stefania De Propris, Erika Borlenghi, Francesco Di Raimondo, Michela Ansuinelli, Caterina Alati, Daniele G. Mattei, Valentina Mancini, Patrizia Chiusolo, Barbara Scappini, Maria Paola Martelli, Prassede Salutari, Marco Cerrano, Bianca Serio, Antonella Cucca, Mario Luppi, Daniele Vallisa, Crescenza Pasciolla, Claudio Romani, Martina Chiarucci, Federico Mosna, Massimiliano Bonifacio, Nicola Stefano Fracchiolla, Monica Bocchia, Silvia Imbergamo, Catello Califano, Giuseppe Rodolfo Nunziata, Mario Annunziata, Antonino Mule', Patrizia Zappasodi, Fabio Giglio, Daniela Pietrasanta, Matteo Della Porta, Maurizio Musso, Monia Lunghi, Francesco Zaja, Elisabetta Todisco, Claudia Maria Basilico, Alfonso Piciocchi, Paola Fazi, Alessandro Rambaldi, Robin Foà

Blood (2025) 146 (Supplement 1): 439.

https://doi.org/10.1182/blood-2025-439

Published: 2025

Journal Articles

Efficacy and safety of a retreatment with inotuzumab ozogamicin in adult patients with relapsed/refractory acute lymphoblastic leukemia: A Campus ALL study

Blood (2025) 146 (Supplement 1): 5127.

https://doi.org/10.1182/blood-2025-5127

Published: 2025

Journal Articles

10-day decitabine versus conventional chemotherapy (“3+7”) followed by allografting in AML patients ≥ 60 years: Long-term follow-up results of the randomized phase III trial AML21 of the EORTC leukemia group, GIMEMA and german MDS Study group

Blood (2025) 146 (Supplement 1): 1676.

https://doi.org/10.1182/blood-2025-1676

Published: 2025

Journal Articles

Up-front blinatumomab improves MRD clearance and outcome in adult Ph – B-lineage ALL: the GIMEMA LAL2317 phase 2 study

Blood (2025) 145 (21): 2447–2459.

https://doi.org/10.1182/blood.2024027500

Published: 2025

Includes: Supplemental data

Journal Articles

How I treat adult Ph + ALL

Sabina Chiaretti, Robin Foà

Blood (2025) 145 (1): 11–19.

https://doi.org/10.1182/blood.2023023152

Published: 2025

Journal Articles

Final Analysis of the Italian Campus ALL Observational Study on 476 Older Patients with Philadelphia-Negative Acute Lymphoblastic Leukemia

Marco Cerrano, Lazzarotto Davide, Eleonora Boscaro, Erika Borlenghi, Ilaria Tanasi, Patrizia Chiusolo, Paola Minetto, Francesco Grimaldi, Michelina Dargenio, Matteo Leoncin, Silvia Trappolini, Cristina Papayannidis, Fabio Forghieri, Carmela Gurrieri, Patrizia Zappasodi, Roberta La Starza, Nicola Fracchiolla, Federica Di Biase, Maria Ilaria Del Principe, Marzia Defina, Crescenza Pasciolla, Benedetta Cambò, Federico Mosna, Daniela Pietrasanta, Sabrina Mariani, Valentina Mancini, Fabio Guolo, Federico Lussana, Elisabetta Todisco, Mario Annunziata, Valeria Calafiore, Maria Ciccone, Matteo Piccini, Matteo Emidio Dragani, Beatrice Sani, Endri Mauro, Claudia Basilico, Beatrice De Marco, Marco Antonacci, Laura Forlani, Monica Fumagalli, Fabio Trastulli, Monia Lunghi, Prassede Salutari, Sara Mastaglio, Sabina Chiaretti, Anna Candoni, Felicetto Ferrara, Giovanni Pizzolo, Robin Foà, Massimiliano Bonifacio

Blood (2024) 144 (Supplement 1): 113.

https://doi.org/10.1182/blood-2024-206854

Published: 2024

Journal Articles

Immunomodulatory Effect of Dasatinib Plus Blinatumomab Versus Ponatinib Plus Blinatumomab in Newly Diagnosed Ph + Acute Lymphoblastic Leukemia Patients

Michela Ansuinelli, Maria Stefania De Propris, Maria Cristina Puzzolo, Nadia Peragine, Tiziano Quacquarelli, Saveria Capria, Cristina Skert, Valentina Mancini, Simona Sica, Federico Lussana, Erika Borlenghi, Marco Cerrano, Daniele Vallisa, Valeria Cardinali, Sabina Chiaretti, Anna Guarini, Robin Foà

Blood (2024) 144 (Supplement 1): 838.

https://doi.org/10.1182/blood-2024-208827

Published: 2024

Journal Articles

Digital Twins As Control Groups to Accelerate Assessment of Safety and Efficacy of Novel Treatment Strategies in Ph-Negative Acute Lymphoblastic Leukemia

Alfonso Piciocchi, Monica Messina, Giovanni Marsili, Marta Cipriani, Francesca Paola Paoloni, Davide Lazzarotto, Anna Candoni, Alessandro Rambaldi, Matteo Leoncin, Paola Fazi, Marco Vignetti, Robin Foà, Sabina Chiaretti

Blood (2024) 144 (Supplement 1): 274.

https://doi.org/10.1182/blood-2024-200643

Published: 2024

Journal Articles

Novel Tools to Improve the Challenging Diagnosis of Ph-like ALL. Comparison between Optical Genome Mapping and Digital-MLPA

Gianfranco Lapietra, Deborah Cardinali, Adela Cisneros, Marco Beldinanzi, Alberto Hernández Sánchez, Francesca Kaiser, Jordi Ribera, Josgrey Del Valle Del Valle Navas Acosta, Jesus Maria Hernandez Rivas, Anna Torrent, Isabel Granada, Jose Tomas Navarro, Robin Foà, Maurizio Martelli, Alberto Orfao, Josep-Maria Ribera, Sabina Chiaretti

Blood (2024) 144 (Supplement 1): 5919.

https://doi.org/10.1182/blood-2024-208697

Published: 2024

Journal Articles

Measurable Residual Disease Monitoring for Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ALL) in the Setting of the Gimema ALL2820 Trial

Blood (2024) 144 (Supplement 1): 2836.

https://doi.org/10.1182/blood-2024-210731

Published: 2024

Journal Articles

Efficacy and Toxicity of Frontline Ponatinib Plus Blinatumomab for Adult Ph+ ALL Patients of All Ages. Intermediate Analysis of the Gimema ALL2820

Blood (2024) 144 (Supplement 1): 835.

https://doi.org/10.1182/blood-2024-207892

Published: 2024

Journal Articles

Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trial

Blood (2024) 144 (5): 541–551.

https://doi.org/10.1182/blood.2023023625

Published: 2024

Includes: Supplemental data

Journal Articles

Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel

Nicola Gökbuget, Nicolas Boissel, Sabina Chiaretti, Hervé Dombret, Michael Doubek, Adele Fielding, Robin Foà, Sebastian Giebel, Dieter Hoelzer, Mathilde Hunault, David I. Marks, Giovanni Martinelli, Oliver Ottmann, Anita Rijneveld, Philippe Rousselot, Josep Ribera, Renato Bassan

Blood (2024) 143 (19): 1891–1902.

https://doi.org/10.1182/blood.2023020794

Published: 2024

Includes: Supplemental data

Journal Articles

Management of ALL in adults: 2024 ELN recommendations from a European expert panel

Blood (2024) 143 (19): 1903–1930.

https://doi.org/10.1182/blood.2023023568

Published: 2024

Includes: Supplemental data

Journal Articles

Real-Life Efficacy and Safety of Vemurafenib Plus Rituximab (V+R) in Relapsed or Refractory Hairy Cell Leukemia: A Multi-Center Retrospective Study (HCL-PG03R)

Blood (2023) 142 (Supplement 1): 3027.

https://doi.org/10.1182/blood-2023-178648

Published: 2023

Journal Articles

Efficacy and Safety of Obinutuzumab in Relapsed or Refractory Hairy Cell Leukemia (R/R HCL): An Italian Multicenter Phase-2 Academic Trial (HCL-PG04)

Enrico Tiacci, Luca De Carolis, Monia Capponi, Flavio Falcinelli, Francesco Zaja, Alessandro Pulsoni, Edoardo Simonetti, Elisa Montechiarello, Alessandra Romano, Jacopo Olivieri, Alessandro Mancini, Gianna Maria D'Elia, Robin Foa, Maurizio Frezzato, Brunangelo Falini

Blood (2023) 142 (Supplement 1): 4398.

https://doi.org/10.1182/blood-2023-180035

Published: 2023

Journal Articles

CD49d Expression Is Included in a Revised 4-Factor Model Predicting Outcome in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Multi-Center Real-World Experience

Blood (2023) 142 (Supplement 1): 3281.

https://doi.org/10.1182/blood-2023-174897

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Elevation of fetal hemoglobin is a biomarker for response to decitabine in AML: Results of the AML21 randomized phase III trial of the EORTC leukemia group, gimema and german MDS study group

Asciminib for relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) and lymphoid blast crisis of chronic myeloid leukemia (LBC-CML) in Italy: A Campus ALL real life study

Clinical impact of untargeted baseline plasma metabolomics in newly diagnosed diffuse large B-cell lymphoma

First results of the Phase III GIMEMA ALL2820 trial comparing ponatinib plus blinatumomab to imatinib and chemotherapy for newly diagnosed adult ph+ acute lymphoblastic leukemia patients

Efficacy and safety of a retreatment with inotuzumab ozogamicin in adult patients with relapsed/refractory acute lymphoblastic leukemia: A Campus ALL study

10-day decitabine versus conventional chemotherapy (“3+7”) followed by allografting in AML patients ≥ 60 years: Long-term follow-up results of the randomized phase III trial AML21 of the EORTC leukemia group, GIMEMA and german MDS Study group

Up-front blinatumomab improves MRD clearance and outcome in adult Ph – B-lineage ALL: the GIMEMA LAL2317 phase 2 study

How I treat adult Ph + ALL

Final Analysis of the Italian Campus ALL Observational Study on 476 Older Patients with Philadelphia-Negative Acute Lymphoblastic Leukemia

Immunomodulatory Effect of Dasatinib Plus Blinatumomab Versus Ponatinib Plus Blinatumomab in Newly Diagnosed Ph + Acute Lymphoblastic Leukemia Patients

Digital Twins As Control Groups to Accelerate Assessment of Safety and Efficacy of Novel Treatment Strategies in Ph-Negative Acute Lymphoblastic Leukemia

Novel Tools to Improve the Challenging Diagnosis of Ph-like ALL. Comparison between Optical Genome Mapping and Digital-MLPA

Measurable Residual Disease Monitoring for Philadelphia Positive Acute Lymphoblastic Leukemia (Ph+ALL) in the Setting of the Gimema ALL2820 Trial

Efficacy and Toxicity of Frontline Ponatinib Plus Blinatumomab for Adult Ph+ ALL Patients of All Ages. Intermediate Analysis of the Gimema ALL2820

Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trial

Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel

Management of ALL in adults: 2024 ELN recommendations from a European expert panel

Real-Life Efficacy and Safety of Vemurafenib Plus Rituximab (V+R) in Relapsed or Refractory Hairy Cell Leukemia: A Multi-Center Retrospective Study (HCL-PG03R)

Efficacy and Safety of Obinutuzumab in Relapsed or Refractory Hairy Cell Leukemia (R/R HCL): An Italian Multicenter Phase-2 Academic Trial (HCL-PG04)

CD49d Expression Is Included in a Revised 4-Factor Model Predicting Outcome in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Multi-Center Real-World Experience

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only